Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

34,100

Employees34,100

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

34,100

Employees34,100

BMY Key Statistics

Market cap

93.94B

Market cap93.94B

Price-Earnings ratio

18.70

Price-Earnings ratio18.70

Dividend yield

5.31%

Dividend yield5.31%

Average volume

10.01M

Average volume10.01M

High today

$46.80

High today$46.80

Low today

$46.02

Low today$46.02

Open price

$46.24

Open price$46.24

Volume

14.35M

Volume14.35M

52 Week high

$63.33

52 Week high$63.33

52 Week low

$42.96

52 Week low$42.96

BMY News

TipRanks 3d

Bristol-Myers Squibb: Hold Rating Amid Slower Cobenfy Launch and Fair Valuation

Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Bristol-Myers Squibb. The associated price target remains the same with $47.00. Eleva...

Simply Wall St 3d

Promising Lung Cancer Trial Results Could Be a Game Changer for Bristol-Myers Squibb

BioNTech SE and Bristol-Myers Squibb announced promising interim data from a global Phase 2 trial evaluating pumitamig combined with chemotherapy in extensive-s...

Simply Wall St 4d

BioNTech Faces Legal Challenges Over mRNA Patent

has been under scrutiny due to significant legal challenges, including a recent claim construction ruling in a patent lawsuit involving its COVID-19 mRNA vaccin...

Analyst ratings

72%

of 29 ratings

Buy

24.1%

Hold

72.4%

Sell

3.4%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.